SCHEMBL10282575

SCHEMBL10282575

CCN[C@@H](CC)CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10282542 1.00
SCHEMBL1719954 1.00
SCHEMBL1742998 0.90 LMNA (0.58)
SCHEMBL2348889 0.88
Ethambutol SCHEMBL4029 0.82 LMNA (1.00)
Ethambutol SCHEMBL2636850 0.82 LMNA (1.00)
Ethambutol SCHEMBL15479016 0.82 LMNA (1.00)
Ethambutol SCHEMBL3399 0.82 LMNA (1.00)
Ethambutol SCHEMBL2961583 0.82 LMNA (1.00)
Ethambutol SCHEMBL9906602 0.82 LMNA (1.00)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2535345-A1 Anticancer nucleoside analogs BioCryst Pharmaceuticals, Inc. (US) 2012-12-19 EP disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20070293511-A1 Crf Receptor Antagonists and Methods SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION 2007-12-20 US disclosed